Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed May 21, 2024
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Stock Option (Right to Buy)
2024-05-20+528,000→ 528,000 totalExercise: $2.01Exp: 2034-05-19→ Common Stock (528,000 underlying)
Footnotes (1)
- [F1]The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.